Abstract
Introduction: Triple therapy with protease inhibitors, telaprevir and boceprevir, is the new standard of treatment for hepatitis C virus (HCV) genotype 1 infection. In this study, we investigated the natural history of anemia in patients treated with triple therapy compared to those treated with pegylated-interferon and ribavirin (PEG/RBV) in the real-life setting. Methods: Anemia was monitored in 72 consecutive patients treated with telaprevir- (46) or boceprevir-based triple therapy (26) for 16 weeks. These patients were statistically matched to 72 controls with respect to age, sex, race, and fibrosis that were treated previously with PEG/RBV. Anemia was treated by dose RBV dose reduction, red blood cell (RBC) transfusions, or epoetin alfa injections (EPO). Results: The mean age for the study population was 52.1 years, 58.3% were male, 41.4% were treatment naive, and 30.3% were cirrhotic. The control group was similar in terms of age, sex, race, and fibrosis. The mean baseline hemoglobin was 14.8 ± 1.3 g/dL. Incidence of grade 2-4 anemia (hemoglobin<10g/dL) in patients was 50% for those treated with telaprevir, 50% for those treated with boceprevir, and 27.5% treated with PEG/RBV (p<0.005). Lowest mean hemoglobin was 10.3 ± 1.8 g/dL, 10.4 ± 1.8 g/dL, and 11.0 ± 1.8 g/dL for telaprevir, boceprevir, and controls respectively (p<0.061). Hemoglobin nadir was reached between treatment weeks 6-10 in all treatment arms. Anemia required RBV dose reduction in 60% of those on telaprevir, 57.1% of those on boceprevir and 17.9% of the controls (p<0.001). PEG dose reduction, use of EPO, and/or RBC transfusion was not significantly different between the three groups. None of the patients had to discontinue HCV therapy due to anemia. Conclusion: Using protease inhibitors such as telaprevir or boceprevir to treat patients with hepatitis C results in more significant anemia when compared to treatment with PEG/RBV alone. Ribavirin dose reduction was used more frequently in patients treated with protease inhibitors compared to controls; however, the need for RBC transfusions, EPO injections, and PEG dose reduction was similar in both groups.
Highlights
Triple therapy with protease inhibitors, telaprevir and boceprevir, is the new standard of treatment for hepatitis C virus (HCV) genotype 1 infection
We investigated the development, natural history, and management of anemia in patients who were treated with telaprevir or boceprevir in the real life setting outside of clinical trials
The mean age of patients treated with telaprevir and boceprevir was 52.1 years, 58.3% were male, 41.4% were treatment naive, and 30.3% were cirrhotic
Summary
Triple therapy with protease inhibitors, telaprevir and boceprevir, is the new standard of treatment for hepatitis C virus (HCV) genotype 1 infection. We investigated the natural history of anemia in patients treated with triple therapy compared to those treated with pegylated-interferon and ribavirin (PEG/RBV) in the real-life setting. The sustained virologic response (SVR) for patients with HCV genotype 1 infection was approximately 40% with this previous standard of therapy of pegylated interferon (PEG) and ribavirin (RBV) [3]. In 2011, protease inhibitors, telaprevir and boceprevir, were brought out of phase III clinical trials into the real life setting and have since played a revolutionary role in the treatment for hepatitis C virus genotype 1 infection [4]. Anemia has emerged as the most significant adverse event associated with both protease inhibitors
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have